Dassault pays 10 times revenue for ArisGlobal as Life Sciences stalls

Dassault Systèmes has closed its $1.8bn cash purchase of ArisGlobal, which adds two points to fourth quarter growth. Its Life Sciences software revenue fell 2% in nine months at constant currency, and the company promises growth in 2027.

Dassault's 2027 Life Sciences growth is already bought. ArisGlobal is about 15% of the unit's annualised revenue, so reported growth turns positive next year whatever MEDIDATA, the clinical trials platform, does. The number to watch is MEDIDATA's own growth, and the first test is the Capital Markets Day on 17 November.

Dassault Systèmes has completed its purchase of ArisGlobal for $1.8 billion in cash. Up to $200 million more is tied to AI revenue milestones. The deal was agreed on 23 July and closed in the second half of September.

On 28 October the company raised its 2026 guidance. Reuters calls it the first upgrade in two years.

Dassault paid about 10 times ArisGlobal's expected revenue. That is roughly twice the multiple the market puts on Dassault itself. The unit it is fixing, built on MEDIDATA, has stopped growing.

Life Sciences before the acquisition

The segment has shrunk this year. In its third quarter release, Dassault reports Life Sciences software revenue of EUR776.7 million for nine months, against EUR817.5 million a year earlier. That is a fall of 2% at constant currency and 5% as reported.

The third quarter alone rose 1% at constant currency and 4% as reported, to EUR266 million. MEDIDATA was flat.

Life Sciences is 19% of Dassault's software revenue, so the unit is the drag. Over the same nine months the group grew 4% at constant currency to EUR4.62 billion.

Management says the turn comes next. On the results call, as transcribed by Investing.com, chief executive Pascal Daloz said MEDIDATA was flat this quarter and growth returns in the fourth. He added: "we are going to grow next year".

The chief financial officer put it more carefully: MEDIDATA is "on track to deliver growth from Q4 onwards". The release says bookings are accelerating MEDIDATA's annual recurring revenue growth, which feeds revenue with a lag.

What Dassault paid

The purchase price deserves closer attention. The July announcement put ArisGlobal's expected 2026 revenue at $175 million. The $1.8 billion cash price is therefore 10.3 times that revenue. It is 11.4 times if the full $200 million of milestones is paid.

By our calculation Dassault itself is valued at about 4.8 times revenue. Market value is about EUR31.6 billion, from 1,324 million shares at the EUR23.90 close on 28 October. Less EUR1.05 billion of net cash, that is divided by the EUR6.43 billion midpoint of the 2026 revenue guide.

So Dassault paid roughly twice its own multiple. For Medidata in 2019 it paid $5.8 billion, 9.1 times the $636 million of revenue Medidata booked in 2018.

There are reasons to expect growth. ArisGlobal sells regulated safety software to more than 200 clients, including half of the top 50 global biopharma companies. It has more than 1,300 employees and processes more than 12 million patient safety reports a year.

Dassault's July release cites margins consistent with its own. It puts the compliance market at $7.5 billion by 2030.

The chief financial officer projects double digit growth for ArisGlobal in 2027, Reuters reported. The group is guided to 4% to 5% in 2026, so a high multiple can shrink quickly. One year at 15% growth would take $175 million to about $201 million and the cash price down to 8.9 times (our illustration).

The milestones are about 11% of the cash price. The $1.8 billion in cash is paid up front, so the buyer carries the risk if growth slips.

How ArisGlobal changes the growth figures

The deal lifts the group numbers now. Dassault's fourth quarter guide says ArisGlobal adds two points of growth. The chief financial officer puts one point at about EUR18 million, so two points is about EUR36 million for the quarter.

Full year revenue growth is now 4% to 5% at constant currency, narrowed from 3% to 5%. Earnings per share growth is lifted to 6% to 7% at constant currency, or 3% to 4% as reported, and includes ArisGlobal. Operating margin is now 32.5% to 32.7%.

The fourth quarter guide is EUR1.782 billion to EUR1.842 billion of revenue, up 5% to 8% at constant currency. Its margin is 37.2% to 37.8%.

Dassault paid from its own cash, with no debt and no new shares. The chief financial officer said year to date operating cash flow had already funded the EUR1.5 billion cost. Nine month operating cash flow was EUR1.57 billion.

Net cash was still EUR1.05 billion at 30 September, after repaying EUR900 million of borrowings.

ArisGlobal’s revenue more than offsets the unit’s decline. A year of its revenue, about EUR151 million, is about nine times the EUR16 million constant currency fall in nine month revenue. That uses Dassault's plan rate of $1.16 per euro on $175 million, and ArisGlobal is about 15% of the unit's annualised EUR1,036 million.

On a nine month footing ArisGlobal's EUR113 million is almost three times the EUR41 million reported decline. Reported growth will therefore turn positive whatever MEDIDATA does. The useful measure is MEDIDATA growth with ArisGlobal taken out.

Who is responsible for integration

Dassault has also changed who answers for the result. Dr Ashwini Zenooz is now executive vice president and chief executive of Life Sciences and Healthcare, reporting to Pascal Daloz. She was formerly with the US Department of Veterans Affairs and Salesforce.

She leads MEDIDATA, which runs across 42,000 trials and 13 million patients, along with BIOVIA and ArisGlobal. ArisGlobal chief executive Aman Wasan stays.

Per the release she is responsible for strategy, integration and the P&L (profit and loss) across the three. Her new role puts one person in charge of the integration.

On 17 November Dassault should say how much of the 2027 Life Sciences growth comes from ArisGlobal, about 15% of the unit's annualised revenue. If MEDIDATA is still close to flat, almost all of that growth is bought. Fourth quarter results on 3 February 2027 give the first quarter with ArisGlobal in full.